Welcome to our dedicated page for Corbus Pharmaceu news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceu stock.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage oncology and obesity company whose news flow is driven by clinical trial progress, regulatory milestones, and capital markets activity. The company regularly issues press releases on Phase 1 and Phase 2 data for its investigational drug candidates, as well as updates on financing transactions and participation in major healthcare conferences.
Investors following CRBP news can expect detailed updates on CRB-701, Corbus’ Nectin-4–targeting antibody-drug conjugate being studied in a multi-center Phase 1/2 trial in advanced solid tumors such as head and neck squamous cell carcinoma, cervical cancer, and metastatic urothelial cancer. News items have highlighted objective response rates, disease control rates, safety findings, and Fast Track designations granted by the U.S. Food and Drug Administration. Corbus also announces presentations of CRB-701 data at scientific meetings like the European Society for Medical Oncology Congress and associated key opinion leader events.
Another major news theme is the company’s obesity program, particularly CRB-913, a highly peripherally restricted oral CB1 receptor inverse agonist. Corbus has reported results from a Phase 1a SAD/MAD study in the United States, including safety, tolerability, pharmacokinetic data, and emerging evidence of weight loss in people with obesity. Subsequent news covers the initiation and design of the 12‑week CANYON‑1 Phase 1b study in obese, non-diabetic participants.
Corbus’ news feed also includes quarterly financial results, preliminary financial updates via Form 8‑K, and announcements of underwritten public offerings of common stock and pre-funded warrants. In addition, the company frequently discloses its participation in investor conferences and healthcare symposia, where it presents corporate overviews and engages in one-on-one investor meetings. Bookmarking the CRBP news page on Stock Titan allows readers to track these clinical, regulatory, and financing developments in one place.
Corbus Pharmaceuticals announced an aggregate of $71 million in proceeds from an at-the-market offering, selling 9,167,080 shares at a weighted average price of $7.70 per share. The company also secured a $50 million debt facility with K2 HealthVentures, receiving the first $20 million tranche. With $101 million in cash on hand, Corbus expects to fund operations into Q3 2021. This funding enhances the company's strategic flexibility, particularly following Phase 3 clinical readouts.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) appointed George Golumbeski, Ph.D., to its Board of Directors. Dr. Golumbeski brings extensive experience from his roles at Celgene and Novartis, enhancing the company's leadership ahead of crucial data readouts this summer. He emphasizes the importance of Corbus' focus on unmet medical needs, especially regarding lenabasum, a first-in-class treatment for systemic sclerosis and dermatomyositis, which currently lack approved therapies. The addition aims to strengthen Corbus as it evolves from a pre-commercial to a commercial stage.
Corbus Pharmaceuticals (NASDAQ: CRBP) presented data from three abstracts at the 6th Systemic Sclerosis World E-Congress, indicating that the ACR CRISS score correlates positively with patient-reported outcomes in systemic sclerosis (SSc) over two years. The ACR CRISS score is the primary endpoint for the upcoming RESOLVE-1 Phase 3 study of lenabasum, with topline data expected in summer 2020. A satellite symposium will discuss the endocannabinoid system's role in chronic inflammation and fibrosis during the Congress.
Corbus Pharmaceuticals announced the completion of the final visit in their Phase 2b trial of lenabasum for cystic fibrosis, which enrolled 426 participants. The primary endpoint focuses on reducing pulmonary exacerbations (PEx). Topline results are expected in Q3 2020, supported by a $25 million Development Award from the Cystic Fibrosis Foundation. Lenabasum has received Orphan Drug and Fast Track designations from FDA and EMA. Despite currently being unapproved, lenabasum shows promise in reducing inflammation and fibrosis, addressing a significant unmet need in CF treatment.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced progress in its Phase 2b study of lenabasum, aimed at treating cystic fibrosis, with a focus on patients at high risk for pulmonary exacerbations. The study's baseline demographics and disease characteristics were published in the Journal of Cystic Fibrosis. Topline results are expected in late summer 2020. Lenabasum is designed to target the endocannabinoid system, with prior studies showcasing its potential in reducing inflammation and fibrosis. It has shown acceptable safety profiles but remains unapproved for any conditions.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) announced the completion of the last subject's final visit in its RESOLVE-1 Phase 3 trial of lenabasum for systemic sclerosis (SSc), a serious autoimmune disease affecting around 200,000 individuals in the U.S., EU, and Japan. The trial's topline results are expected in summer 2020. Lenabasum has received Orphan Drug and Fast Track designations from the FDA, with promising efficacy observed in prior studies. Notably, there are currently no FDA-approved therapies for SSc.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced the publication of two abstracts at the EULAR 2020 E-Congress, scheduled for June 3-6, 2020. The first abstract details pre-clinical data that connects lenabasum to the inhibition of inflammasome activation, while the second outlines baseline characteristics of patients in the RESOLVE-1 study in Europe. Lenabasum is a novel oral drug designed to address inflammation and fibrosis, exhibiting promising results in various studies.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) announced that CEO Yuval Cohen will present at two upcoming virtual investor conferences. The 2020 RBC Capital Markets Global Healthcare Conference is scheduled for May 19, 2020, at 10:55 AM EST, and the Jefferies Virtual Global Healthcare Conference will take place on June 4, 2020, at 11:00 AM EST. Both presentations will include a fireside chat discussion and Q&A. Audio webcasts will be available on the Corbus website, with replays archived for 90 days. Corbus focuses on developing therapies targeting the endocannabinoid system for various diseases.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported Q1 2020 financial results, revealing a net loss of approximately $29.7 million and a revenue decrease to $1.8 million. The company reaffirmed that topline results from the Phase 3 RESOLVE-1 study for lenabasum in systemic sclerosis are on track for summer 2020, followed by Phase 2b cystic fibrosis data. A public offering raised $46 million in gross proceeds. Corbus is also preparing for a potential NDA submission and commercial launch of lenabasum while implementing a COVID-19 mitigation plan to maintain clinical study integrity.
Summary not available.
FAQ
What is the current stock price of Corbus Pharmaceu (CRBP)?
What is the market cap of Corbus Pharmaceu (CRBP)?
